Introduction {#S0001}
============

Asthma is a common chronic disorder of the airway involving complex interactions among airflow obstruction, airway hyperresponsiveness (AHR), and underlying bronchial inflammation \[[@CIT0001]\]. Airway inflammation and AHR are recognized as major features of bronchial asthma \[[@CIT0002]\]. Because of these observations, it has been suggested that monitoring of airway inflammation and bronchial responsiveness may be useful for gauging the severity of the disease and the efficacy of the anti-inflammatory treatment \[[@CIT0003]\]. Moreover, airway inflammation also appears to be a major factor determining the degree of AHR \[[@CIT0002]\] and may also be reflected by the levels of exhaled nitric oxide (FeNO) \[[@CIT0004]\].

Airway hyperresponsiveness is usually measured by bronchial challenge with direct or indirect stimuli. Because AHR to indirect stimuli is dependent on the presence of inflammatory cells and release of their mediators in addition to a responsive muscle, it is considered more reflective of airway inflammation than airway geometry \[[@CIT0005]\]. Mannitol dry powder (MDP) is a new indirect bronchial provocation test, consisting of a hyperosmolar challenge comparable to hypertonic saline (HS) solution \[[@CIT0006]\]. Mannitol acts as an osmotic stimulus on the cells in the airway mucosa and is thought to simulate the dehydration of the airway surface liquid, leading to the release of bronchoconstricting mediators from inflammatory cells, and causing smooth muscle contraction in responsive individuals \[[@CIT0007]\].

MDP challenge is easier, quicker to perform and better tolerated than HS or methacholine, especially in children, and it shows comparable accuracy of exercise testing in diagnosing asthma \[[@CIT0008]--[@CIT0010]\]. In the light of the above consideration, it is likely to become one of the standard bronchial challenge tests in clinical practice and the research field \[[@CIT0011]\]. The FeNO is a non-invasive marker of eosinophilic airway inflammation, accepted by the PRACTALL Consensus Report as a complementary item in the follow-up of bronchial inflammation \[[@CIT0012]\].

Few studies have been conducted to evaluate the relationship between airway hyperresponsiveness by using the mannitol challenge test and FeNO in atopic asthmatic children \[[@CIT0013], [@CIT0014]\]. In fact, children with intermittent and mild persistent allergic asthma represent a special study population. The presence of atopy, as postulated by Suh DI and colleagues, could better reflect the link between AHR to mannitol and FeNO \[[@CIT0015]\]. On the basis of this knowledge, the primary aim of this study was to evaluate the correlation between AHR to mannitol and bronchial inflammation measured as FeNO levels in a population of children with intermittent and mild persistent allergic asthma.

Studies in the literature have postulated that poorly or uncontrolled asthma may be associated with bronchial inflammation (in terms of increased FeNO levels). As well as airway inflammation, asthma control is likely to be influenced by the degree of AHR \[[@CIT0016]\]. The recent update of the Global Initiative for Asthma (GINA) guidelines has placed emphasis on the concept of asthma control as being the key target of treatment \[[@CIT0017]\]. In this direction several validated questionnaires have been proposed to assess asthma control in children and young adults \[[@CIT0018], [@CIT0019]\]. Previous studies have demonstrated that the Asthma Control Test (ACT) is a useful tool in addition to clinical and functional evaluation in the management of asthma \[[@CIT0020]\].

Therefore ACT was assessed in the present study for the first time, with the secondary aim to evaluate whether asthma control correlates with AHR to mannitol and FeNO.

Material and methods {#S0002}
====================

Study design {#S20003}
------------

This was a cross-sectional study. Subjects were asked to come for one study visit. In order to avoid any possible influence on bronchial reactivity, they were asked to refrain from taking current conventional agents in the treatment of asthma \[[@CIT0021], [@CIT0022]\], such as inhaled corticosteroids (ICSs), leukotriene receptor antagonists (LTRAs) and long-acting β~2~-agonists (LABAs) for 4 weeks before the study day as a run-in period to be enrolled in the study protocol. We considered this period sufficient to wash-out from any asthma medications, as suggested by Anderson *et al*. \[[@CIT0023]\]. During this period all children were followed closely. Every 3 days we performed phone questionnaires in order to determine any occurrence of respiratory symptoms, and parents were asked to inform us as soon as possible. On arrival, the clinical diagnosis of asthma was confirmed by a pediatric respiratory staff physician by examination and medical history. During the appointment, all children underwent FeNO analysis before the baseline lung function test measurements, as basal assessment for the mannitol challenge test protocol. Furthermore, an indirect challenge with mannitol dry powder was performed. For assessing the clinical control of asthma, before the challenge test, we asked subjects to fill out a validated Italian translation of the ACT questionnaire (ACT English version available at [www.asthmacontrol.com-Italy/Italian](http://www.asthmacontrol.com-Italy/Italian) final version 09 June 06-Mapi Research Institute).

The ACT provides numerical values to distinguish different levels of control.

Subjects {#S20004}
--------

Forty asthmatic patients were recruited at the Pediatric Allergy and Respiratory Diseases Unit of the Department of Pediatrics, "G. D\'Annunzio" University of Chieti, Chieti, Italy.

These 40 subjects met the American Thoracic Society-European Respiratory Society (ATS-ERS) criteria for asthma \[[@CIT0024]\], had a history of wheezing and chest tightness, and were previously diagnosed by a pediatric respiratory physician as having asthma. All children were classified as having intermittent or mild persistent asthma based on the GINA guidelines \[[@CIT0025], [@CIT0026]\]. The skin prick test (SPTs) and total and specific serum IgE levels were performed. The study population was characterized by atopic children, who were IgE-sensitized, with a measurable level of allergen-specific IgE. Exclusion criteria for patient recruitment were: 1) history of upper and lower airway infection over the 4 weeks preceding the study; 2) congenital abnormalities of cardio-respiratory system, chest or skeletal deformities, or neuromuscular system disease, chronic and autoimmune disease, gastro-esophageal reflux; 3) any other condition impeding performance of lung function tests.

Written informed consent was obtained from all parents and children older than 12 years, and oral consent from all children.

The study was approved by the Ethical Committee of the University of Chieti.

Mannitol challenge test {#S20005}
-----------------------

The mannitol challenge test (MCT) was performed according to the protocol of Anderson and co-workers using a single dose Inhalator (Boehringer Ingelheim, Ingelheim, Germany) \[[@CIT0007]\]. The dose protocol consisted of 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160 and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg. The 80-mg and 160-mg doses were given in multiples of 40 mg capsules. Children were asked to inhale from the device from near to functional residual capacity (FRC) to near to total lung capacity (TLC), and to subsequently hold their breath for 5 s. Children had a nose clip on during inhalation and were asked to exhale through their mouth to minimize deposition in the nasopharynx. Three forced expiratory maneuvers were performed 60 s after each dose, and the highest forced expiratory volume in 1 s (FEV~1~) measurement was recorded. The challenge was stopped when a 15% decrease in FEV~1~ was measured or a total cumulative dose of 635 mg had been administered. The FEV~1~ value measured after the 0 mg capsule is taken as the baseline FEV~1~ and is used to calculate the percentage decrease in FEV~1~ in response to the mannitol challenge. The provoking dose of mannitol to induce a 15% fall in FEV~1~ for mannitol was calculated (PD~15~).

Atopic sensitization {#S20006}
--------------------

Atopy was documented by elevated specific serum IgE or by a positive SPTs to at least one of the aero-allergens \[[@CIT0027]\]. SPTs were performed following the European Academy of Allergy and Clinical Immunology (EAACI) guidelines. A positive result was defined as a wheal at least 3 mm in diameter in response to one or more allergens \[[@CIT0028]\].

Determination of allergen-specific IgE, expressed as kUA/l, was made by an Immunoenzymatic Allergo-sorbent Test (Cap test Pharmacia) \[[@CIT0029]\]. The confidence interval is from 0.35 (class 1) to 100 kUA/l (class 5). Class 0 is the default for values up to 0.35 kUA/l, and class 6 is the default for values over 100 kUA/l. The range of positive values of specific serum IgE was above 0.35 kUA/l.

Inflammatory markers {#S20007}
--------------------

In order to evaluate bronchial inflammation status, all children underwent FeNO analysis.

FeNO was determined with an on-line method using a single breath exhalation and a sensitive chemiluminescence assay (Ecomedics CLD 88), according to ATS-ERS \[[@CIT0030]\]. Patients made an inspiration of eNO-free air via a mouthpiece immediately followed by full exhalation at a constant rate (50 ml/s) for at least 5 s. The mean of three acceptable readings at the end of the expiration (plateau phase) was taken as the representative value for each measurement, according to ATS-ERS criteria \[[@CIT0031]\]. The cut-off point for an increased level of FeNO was defined as 16 ppb according to the literature, which showed that FeNO levels higher than 16 ppb had the highest diagnostic value to confirm exercise-induced bronchospasm \[[@CIT0032]\].

Asthma Control: ACT (Asthma Control Test) {#S20008}
-----------------------------------------

The ACT is a straightforward, self-administered questionnaire with five questions on asthma symptoms (such as shortness of breath, wheezing, coughing); use of rescue medications (such as albuterol or salbutamol); and effect of asthma on daily functioning (such as waking up at night or earlier than usual in the morning). For children younger than 11 years the C-ACT questionnaire was used \[[@CIT0019]\], while for children older than 12 years the ACT questionnaire developed by Nathan *et al*. was used \[[@CIT0018]\]. Each item included five response options for children and parents, from 1 (worst) to 5 (best). The lowest and highest possible scores were thus 5 (totally uncontrolled asthma) and 25 (total asthma control), respectively, and a score of 19 or less was shown to be indicative of poorly controlled asthma \[[@CIT0018], [@CIT0019]\].

Statistical analysis {#S20009}
--------------------

The primary outcome of this study was the correlation between FeNO levels (expressed in ppb) and AHR to mannitol in terms of PD~15~. According to data from the literature and clinical experience of the involved investigators, we expected a correlation coefficient of 0.45 between the above two quantitative variables evaluated in this study. Assuming a type I error (α) of 0.05, a group of 35 patients would provide a power (1 -- β) of 80% to detect a difference of 0.45 in the correlation coefficient. These calculations were performed using PASS 2005 (Kaysville, Utah).

All quantitative parameters were expressed as mean ± standard deviation (SD), and all categorical variables were reported as frequency and percentage.

Best values of spirometric measurements of FEV~1~ were considered for statistical evaluation.

The provocative dose of mannitol causing a fall in FEV~1~ of 15% was calculated for all children (PD~15~; measuring airway sensitivity).

The relationship between mannitol PD~15~ and FeNO was reported graphically as a scattergram and evaluated by Pearson\'s correlation coefficient (rp).

After dividing our study population into two groups on the basis of FeNO levels (group A ≥ 16 ppb and group B \< 16 ppb -- cut-off with the highest diagnostic value for exercise-induced bronchoconstriction (EIB)) \[[@CIT0032]\], Student\'s unpaired *t* test was applied to compare the two groups for quantitative parameters. The χ^2^ test was performed to evaluate the difference between groups for categorical variables, and Fisher\'s exact test was used to evaluate the prevalence of allergen sensitization.

A *p*-value less than 0.05 was considered to be statistically significant. All calculations were made with the computer program Statistical Package for the Social Sciences (SPSS), version 16.0 software for Windows.

Results {#S0010}
=======

Forty children (24 males and 16 females) with a mean age of 9.3 ±2.9 years with intermittent and mild persistent asthma were enrolled. Population characteristics are shown in [Table I](#T0001){ref-type="table"}.

###### 

Characteristics of the study population

  Parameter                                           Group A (*n* = 15)   Group B (*n* = 25)   Value of *p*^[a](#TF0001){ref-type="table-fn"}^
  --------------------------------------------------- -------------------- -------------------- -------------------------------------------------
  Age \[years\]                                       10.3 ±2.3            8.7 ±2.6             0.099
  Weight \[kg\]                                       42.7 ±14.3           35.6 ±11.5           0.089
  Height \[cm\]                                       144.9 ±18.9          134.5 ±14.3          0.060
  Gender (M/F)                                        8/7                  16/9                 0.739^[b](#TF0002){ref-type="table-fn"}^
  Total serum IgE \[kU~A~/l\]                         350.3 ±331.8         321.4 ±345.6         0.698
  FeNO \[ppb\]                                        42.8 ±20.1           7.2 ±4.3             \< 0.001
  FEV~1~ baseline (%-predicted)                       103.4 ±10.5          111.7 ±16.5          0.096
  Classification of asthma:                                                                     
   Intermittent vs. mild persistent                   10/5                 22/3                 
  Treatment:                                                                                    
   On-therapy before the study:                       5                    3                    
    ICS \[µg/day\]                                    100                  100                  
    LABA \[mg/day\]                                   --                   --                   --
    ICS + LABA \[µg/day + mg/day\]                    --                   --                   --
    Antihistamines \[mg/day\]                         --                   --                   --
   Off-therapy before the study                       10                   22                   
  Prevalence of allergen sensitization:                                                         
   Dermatophagoides pt. and fa. (%)                   86.7                 92.1                 0.624^[c](#TF0003){ref-type="table-fn"}^
   Rye grass (%)                                      60.1                 56.2                 0.990^[c](#TF0003){ref-type="table-fn"}^
   Olive tree (%)                                     46.7                 32.2                 0.502^[c](#TF0003){ref-type="table-fn"}^
   Wall pellitory (%)                                 46.7                 20.1                 0.091^[c](#TF0003){ref-type="table-fn"}^
   Cat epithelia (%)                                  26.7                 20.2                 0.705^[c](#TF0003){ref-type="table-fn"}^
   *Alternaria alternate* (%)                         6.7                  12.1                 0.990^[c](#TF0003){ref-type="table-fn"}^
   *Aspergillus* spp. (%)                             6.7                  0.9                  0.375^[c](#TF0003){ref-type="table-fn"}^
  Bronchial hyperresponsiveness and asthma control:                                             
   AHR to mannitol (PD~15~) \[mg\]                    154.7 ±97.5          262.8 ±186.5         0.040
   ACT score                                          22.1 ±2.4            24.4 ±1.1            0.001

Values are mean ± SD or number.

Student\'s unpaired t test

Chi-squared test

Fisher\'s Exact test, M -- male, F -- female, FEV~1~ -- forced expiratory volume in 1 s, PD~15~ -- provocative dose causing a 15% decline in FEV~1~, FeNO --fractional exhaled nitric oxide, AHR -- airway hyperresponsiveness, ACT -- asthma control test.

All children underwent a complete clinical and medical history questionnaire evaluation, including questions about parasitic diseases or other allergic diseases, and upper or lower respiratory illnesses. None of the enrolled children suffered from these diseases.

During the enrollment 2 children were excluded because they were unable to perform the MCT as their FEV~1~ values were under 70% of the predicted value for age, gender and height, and one because he was not able to perform reproducible spirometry.

All children had a positive response to MCT, and were IgE-sensitized with a measurable level of allergen-specific IgE (≥ 0.35 kUA/l); thus they were considered atopic.

Pearson\'s correlation test revealed a significant inverse correlation between airway responsiveness (mannitol PD~15~) and FeNO (*rp* = --0.36; *p* = 0.020), as shown in [Figure 1](#F0001){ref-type="fig"}. There was also a significant positive correlation between ACT and PD~15~ (*rp* = 0.36; *p* = 0.020) and a significant negative correlation between ACT and FeNO levels (*rp* = --0.4; *p* = 0.003).

![Scattergram between FeNO and PD15\
FeNO -- exhaled nitric oxide, PD15 -- provocative dose causing a fall in FEV~1~ of 15%.](AMS-12-26847-g001){#F0001}

Based on the results of FeNO values, the study population was divided into two groups: group A (*n* = 15) with FeNO values equal to or above the cut-off of 16 ppb; group B (*n* = 25) with FeNO values under the cut-off of 16 ppb.

In group A, mean mannitol PD~15~ was 154.7 ±97.5 mg, and mean FeNO was 42.8 ±20.1 ppb, while in group B, mean PD15 was 262.8 ±186.5 mg, and mean FeNO was 7.17 ±4.3 ppb.

Regarding the assessment of clinical control of asthma, in group A ACT showed that 13.3% (2 of 15) of subjects of this group had controlled asthma (ACT score 25), 80% (12 of 15) of subjects had partly controlled asthma (ACT score 20-24) and 6.7% (1/15) had uncontrolled asthma (ACT \< 19). In group B ACT showed that 72% (18 of 25) of subjects of this group had well-controlled asthma (ACT score 25), and 28% (7 of 25) of subjects had partly controlled asthma (ACT score 20--24) and nobody had uncontrolled asthma.

Finally, using Student\'s unpaired *t* test, we found that group A had significantly lower values of mannitol PD~15~ compared to group B (154.7 ±97.5 mg vs. 262.8 ±186.5 mg; *p* = 0.040), and significantly lower values of ACT score (22.1 vs. 24.4; *p* = 0.001) ([Table I](#T0001){ref-type="table"}).

Discussion {#S0011}
==========

The results of the present study revealed that the AHR to mannitol correlates with FeNO levels and ACT score.

In the literature, there are few studies that evaluate the correlation between the MCT and bronchial inflammation by FeNO in childhood \[[@CIT0011], [@CIT0013], [@CIT0014]\]. In addition, no study correlates this challenge test with a validated asthma questionnaire.

Several studies have suggested a causal relationship between airway inflammation and hyperresponsiveness in allergic asthma based mainly on the observation that acute exposure to allergens caused enhanced airway responsiveness and inflammatory cell recruitment in the airways \[[@CIT0033], [@CIT0034]\]. In the study of Leuppi *et al*. \[[@CIT0035]\], raised FeNO levels, in atopic children, are associated with AHR, suggesting that exhaled NO is more than just a marker for atopy. Moreover, our data appear to be consistent with the findings of Sverrild *et al*. \[[@CIT0013]\], who found in young adults a close association between AHR to mannitol and ongoing airway inflammation.

From the results of this study it also appeared that better control of asthma was linked with a lower degree of AHR to mannitol and improved control of bronchial inflammation. In keeping with these findings, there are studies that have shown that ACT score reflects lung function and bronchial inflammation \[[@CIT0036], [@CIT0037]\] and have confirmed that ACT is complementary to other markers of disease control in asthmatic children, especially in the context of follow-up visits \[[@CIT0038]\].

However, the relationship between the asthma control questionnaire and AHR remains unclear. Many studies have shown that the ACT has no relationship with airway hyperresponsiveness evaluated by the Bruce Protocol and other stress tests \[[@CIT0039], [@CIT0040]\]. In contrast with these observations, our results for the MCT showed that ACT had a direct correlation with AHR and airway inflammation. This apparent contradiction could be explained by the fact that the ACT questionnaire does not include questions about exercise-induced symptoms. As a matter of fact, the ACT and exercise-induced bronchoconstriction measure separate domains of asthma control. Another explanatory factor could be that "poor-perceiver" asthmatic children might modify their behavior and avoid physical activity that could be a trigger for bronchospasm, leading to a vicious circle.

This suggests that AHR to mannitol has a close correlation not only with inflammation but also with clinical symptoms related to asthma. This challenge test is probably more sensitive than the other indirect stimuli in atopic asthmatic children in the detection of AHR and asthma control.

The mannitol challenge test might be used in children with poorly perceived asthma symptoms, with only apparently well-controlled asthma, or in children with EIB in which FeNO levels are elevated \[[@CIT0013]\]. As a matter of fact, a positive test predicts active asthma and potential for EIB, while a negative test might suggest good control of asthma \[[@CIT0041]\]. Moreover, response-dose ratio may be used to monitor an intervention or back titration of steroid dose \[[@CIT0042]\].

The relationship between FeNO and AHR in atopic children indicated in our research is confirmed by several existing studies. In agreement with this suggestion, Steerenberg *et al*. \[[@CIT0043]\] demonstrate that the presence of AHR was positively associated with FeNO only in atopic children. Lúdvíksdóttir *et al*. \[[@CIT0044]\] reported a similar relationship in asthmatic adults. There is a well-established relationship between atopy and increased airway responsiveness in children \[[@CIT0045], [@CIT0046]\]; in fact our data suggest that increased FeNO values may be associated with a mechanism linking these two factors. This may involve inflammatory processes and would support the hypothesis that FeNO is a marker of allergic airway inflammation \[[@CIT0047]\].

Contrary to our findings, many studies have shown a dissociation between airway inflammation and AHR in children with mild intermittent/mild persistent asthma. Particularly, Silvestri *et al*. \[[@CIT0048]\] indicated that FeNO levels did not seem to be accurate predictors of the degree of AHR, measured by using a methacholine challenge test, in children with intermittend/mild persistent asthma. Although the authors reported that the study was of insufficient statistical power, in our opinion a possible explanation for this could be that the response to mannitol is mediated mainly through mast cells, which are responsible for the main release of bronchoconstricting mediators \[[@CIT0049], [@CIT0050]\].

Some limitations of the present study need to be mentioned, such as small sample size and the inclusion of only allergic subjects. Another limitation is the cross-sectional design that limits the possibility to prove the causal relationship. Therefore, additional clinical studies on larger populations including non allergic asthmatic children, with a longitudinal design, are necessary to validate the preliminary data of this study. Our hypothesis is that FeNO reflects eosinophilic inflammation, commonly present in children with allergic asthma. On the other hand, mannitol stimulus recruits many inflammatory cells, not only eosinophils, but also mast cells and their mediators, and actually we do not know which is the main pathway that leads to smooth muscle bronchoconstriction. Further studies on the pathophysiological mechanism of mannitol are needed, and particularly in this kind of asthmatic population.

Another shortcoming of the study is the variability of mannitol-PD~15~, which in our view depends on the small sample study population, not influenced by the treatment. Again the presence of one child in group A with an ACT score value \< 19 may have skewed our results. Nevertheless, we suppose that this value really did not influence our results. As a matter of fact, this patient presented some mild asthma exacerbations 2 weeks before the lung function evaluation and symptoms during exercise that required only "rescue medications" (short-acting β~2~-agonists), for which a period of 8 h was considered sufficient to wash-out \[[@CIT0023]\].

The MCT is safe, available as a convenient and standardized test kit with prefilled dry powder capsules and a single use dry powder inhaler device, employs a standard operating procedure for dose and delivery, and is easier especially in children, with only some cough during the challenge \[[@CIT0051]\].

In conclusion, the results of this study indicate that the mannitol challenge test could be a useful diagnostic tool in clinical practice in order to show a better clinical correlation with asthma symptoms in intermittent and mild persistent atopic asthmatic children.
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